Skip to content

Insmed INSM Net Income

Net Income at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$330.96M+174%
United Therapeutics logo
United TherapeuticsUTHR
$274.9M-14.7%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
-$56.74M-44.4%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$29.49M+88.1%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$727.2M-10.1%
Savara logo
SavaraSVRA
-$37.28M-40.0%

Other financials

Income statement

See full
Revenue$306.0M+230%
Gross profit$258.5M+261%
Operating income-$153.3M+38.2%
EPS (diluted)-$0.76+46.5%

Balance sheet

See full
Cash & equivalents$582.2M+44.4%
Total debt$580.3M-49.2%
Total equity$704.9M+611%
Total assets$2.1B+15.2%

Cash flow

See full
Operating cash flow-$222.7M+15.0%
CapEx$3.5M-65.4%
Free cash flow-$226.2M+16.9%

Valuation

See full
Market cap$23.11B+25.2%
Enterprise value$23.11B+29.9%
P/S28.2×-18.2×

Profitability

See full
Gross margin81.8%+5.3pp
Operating margin-140.6%-43.9pp
Net margin-144.4%-45.3pp
FCF margin-112.5%-35.3pp

Returns & leverage

See full
Return on equity-294.5%
Debt / equity0.8×-10.7×
Current ratio4.5×-1.4×

Where this comes from

Reported directly by Insmed in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: Insmed’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insmed's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Insmed's net income?
Insmed (INSM) reported net income of -$163.56M in Q1 2026.
How has Insmed's net income changed year-over-year?
Insmed's net income increased by 36.3% year-over-year, from -$256.58M to -$163.56M.
What is the long-term trend for Insmed's net income?
Over 4 years (2021 to 2025), Insmed's net income has grown at a 30.9% compound annual growth rate (CAGR), from -$434.65M to -$1.28B.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.